Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a new class of antihyperglycemic drugs that regulate blood sugar levels. [1,2]They carry the risk of euglycemic diabetic ketoacidosis (euDKA), which is rare and also seen in our case. [3,4]
No takes yet. Share an insight, caveat, or question.
Serhat Doğan (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: